bioAffinity Technologies Inc
bioaffinitytech.comWhat Do They Do?
Provides laboratory diagnostic services, including a noninvasive sputum test for early-stage lung cancer, to physicians, while developing tests for other lung diseases and researching cancer treatments.
10-K for FY2025, filed Mar 16, 2026We develop noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry…View ↗
CyPath® Lung addresses the need for noninvasive detection of early-stage lung cancer with the proven ability to detect the leading cancer…View ↗
CyPath® Lung is performed and offered by our wholly owned subsidiary PPLS, a clinical anatomic and pathology laboratory which we acquired…View ↗
In addition to CyPath® Lung, we are advancing development of our flow cytometry+AI platform for companion diagnostic tests targeted at…View ↗
Through our wholly owned subsidiary, OncoSelect® Therapeutics, LLC, we have conducted research that has led to discoveries and advancement…View ↗
Commercial laboratory services, including CyPath® Lung, are performed at our wholly owned subsidiary PPLS which we acquired by purchasing…View ↗
How Do They Make Money?
The lab makes money from fees for patient testing, histology work and medical-director services; testing fees are earned mainly when tests are completed and results are reported, and other service fees when services are performed.
10-K for FY2025, filed Mar 16, 2026Post-acquisition of PPLS, additional revenue streams have been consolidated since September 19, 2023. PPLS generates three sources of…View ↗
-
10-K for FY2025, filed Mar 16, 2026
FY2025 revenue by product or service ↗
$6.2M
-
10-K for FY2025, filed Mar 16, 2026
$6.2M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Health Care, Patient Service
Sold outright
10-K for FY2025, filed Mar 16, 2026 |
81% |
Health Care, Patient Service, FY2025
$5M Sources
|
Sold outright |
|
Histology Service Fees
Sold outright
10-K for FY2025, filed Mar 16, 2026 |
18% |
Histology Service Fees, FY2025
$1.1M Sources
|
Sold outright |
|
Medical Director Fees
Sold outright
|
1.1% |
Medical Director Fees, FY2025
$68.3K Sources
|
Sold outright |
|
Department of Defense Observational Studies
|
<0.1% |
Department of Defense Observational Studies, FY2025
$577 Sources
|
|
|
Other Revenues
|
0.1%
FY2022: 100%
|
Other Revenues, FY2025
$4.9K Sources
|
Who Are Their Customers?
Physicians order CyPath® Lung to help assess patients for lung cancer; PPLS offers the test to physicians and performs it in its clinical laboratory.
10-K for FY2025, filed Mar 16, 2026CyPath® Lung addresses the need for noninvasive detection of early-stage lung cancer with the proven ability to detect the leading cancer…View ↗
CyPath® Lung is performed and offered by our wholly owned subsidiary PPLS, a clinical anatomic and pathology laboratory which we acquired…View ↗
Commercial laboratory services, including CyPath® Lung, are performed at our wholly owned subsidiary PPLS which we acquired by purchasing…View ↗
Do Revenues Turn Into Profits?
No. It lost $14.9M in FY2025.
10-K for FY2025, filed Mar 16, 2026
−$10.6MView ↗
10-K for FY2025, filed Mar 16, 2026
−$14.9MView ↗
10-K for FY2025, filed Mar 16, 2026
−$9.4MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 7, 2026
−$3.4MView ↗
- ▼ −17% (Loss)
- vs −$4.1M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 7, 2026
Open tableView ↗
-
Sep 8, 2026
Regained compliance with Nasdaq listing requirements
Nasdaq confirmed the company can continue trading on the Nasdaq Capital Market.
Sources
8-K, filed Sep 9, 2026
On September 8, 2026, the Company received written notice (the “Written Notice”) from the Staff confirming that the Company has regained…View ↗
-
Aug 18, 2026
Agreed to distribute CyPath Lung through AvMEDICAL
AvMEDICAL will promote the test to federal healthcare agencies, including VA medical centers.
Sources
8-K, filed Aug 18, 2026
On August 18, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release announcing that it has…View ↗
Shrinking. Revenue fell 11% in 3 years, from $6.9M in FY2022 to $6.2M in FY2025, about 4% a year.
Laboratory operations
The older report described Precision Pathology as performing CyPath under a joint development agreement; the latest describes PPLS as a wholly owned subsidiary operating commercial laboratory services.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 16, 2026Following completion of the test validation trial, CyPath® Lung was evaluated independently by Precision Pathology, which developed the…View ↗
Commercial laboratory services, including CyPath® Lung, are performed at our wholly owned subsidiary PPLS which we acquired by purchasing…View ↗
Asthma and COPD diagnostics
The latest report specifies companion diagnostic tests for asthma and COPD, while the older report described diagnostic development for lung diseases more generally.
10-K for FY2022, filed Mar 31, 2023
Cancer treatment research
The latest report focuses therapeutic research on topical treatment for squamous cell skin cancer; the older report described broader cancer-therapy research.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 16, 2026Through our wholly owned subsidiary, OncoSelect® Therapeutics, LLC, our research has led to discoveries and advancement of novel cancer…View ↗
Through our wholly owned subsidiary, OncoSelect® Therapeutics, LLC, we have conducted research that has led to discoveries and advancement…View ↗
Who Do They Compete With?
Competes with LungLife AI, Biodesix, and Veracyte
10-K for FY2025, filed Mar 16, 2026A balanced test called LungLB (sold by LungLife AI in the US) is commercially available as a laboratory developed test and has an insurance…View ↗
Loading...
